ArticleInfectious agents and cancer2026
Differential expression and prognostic role of ACACA, ACLY, and FASN in schistosomiasis-associated versus hepatitis B virus-related liver cancer.
Article in Infectious agents and cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo investigate the clinicopathological differences between schistosomiasis-related liver cancer (Sj-LC) and hepatitis B virus-related liver cancer (HBV-LC), as well as the expression and prognostic significance of key lipid metabolism enzymes (ACACA, ACLY, FASN).
methodsA retrospective analysis was performed on 309 HBV-LC and 44 Sj-LC patients treated at the First Affiliated Hospital of Wannan Medical College from June 2016 to December 2024. AJCC staging was conducted for 183 HBV-LC and 25 Sj-LC cases (June 2016–June 2021). Transcriptome data of 111 HBV-LC cases were retrieved from the Cancer Genome Atlas (TCGA) database for analysis. Gender- and age-stratified tissue samples (Sj-LC, HBV-LC, and normal liver tissues) were subjected to immunohistochemistry (IHC) and quantitative real-time polymerase chain reaction (RT-qPCR) to detect the expression of ACACA, ACLY, and FASN.
resultsCompared with HBV-LC, Sj-LC had a lower male proportion (68.2% vs. 86.1%, P = 0.003), an older age at onset (66.38 ± 8.364 vs. 60.75 ± 11.682 years, P < 0.001), a lower proportion of hepatocellular carcinoma (P < 0.001), higher incidences of gastrointestinal bleeding, hepatic encephalopathy, metastasis, and extrahepatic spread (all P < 0.05), and a more advanced tumor stage (predominantly IVB, P < 0.001). Sj-LC also exhibited higher levels of D-dimer, cholesterol, and triglycerides (all P < 0.01). Bioinformatics analysis showed upregulated expression of ACACA, ACLY, and FASN in HBV-LC. IHC and RT-qPCR results confirmed higher expression of these enzymes in Sj-LC (larger positive areas, stronger staining intensity, and higher amplification folds), with ACLY expression significantly overexpressed compared to normal liver tissues.
conclusionSj-LC exhibits distinct clinicopathological features and lipid metabolism enzyme expression profiles compared with HBV-LC, characterized by older onset age, more complications, stronger invasiveness, and advanced stage at diagnosis. Elevated ACACA, ACLY, and FASN expression suggests that lipid metabolism reprogramming may be associated with the malignant phenotype of Sj-LC. Notably, these enzymes were not confirmed as independent prognostic factors for Sj-LC, and their direct association with prognosis requires further verification in expanded cohorts. Targeted individualized diagnosis, treatment, and early screening strategies are warranted for Sj-LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.